- Phase 2 OLE showed mean pVO2 improvement of 2.7 mL/kg/min and KCCQ-CSS increase of 17.3 points at Week 52.
- 79% of patients achieved Valsalva LVOT gradient below 30 mmHg; 60% reached NYHA Class I.
- Simplified dosing supported, with 57% remaining on initial 40 mg BID dose.
Why is $BRVE moving today? · SEC 8-K archive
$BRVE SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $BRVE: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $BRVE filing catalyst
Why did $BRVE trigger an AI stock catalyst alert?
$BRVE triggered a Stock Catalyst AI alert on 2026-11-06 20:17:17 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Braveheart Bio Reports Positive 52-Week Phase 2 Data for HRS/BHB-1893 in oHCM. Key points: - Phase 2 OLE showed mean pVO2 improvement of 2.7 mL/kg/min and KCCQ-CSS increase of 17.3 points at Week 52. - 79% of patients achieved Valsalva LVOT gradient below 30 mmHg; 60% reached NYHA Class I. - Simplified dosing supported, with 57% remaining on initial 40 mg BID dose.
How did $BRVE stock react after the SEC filing?
After the SEC 8-K for $BRVE, observed market reaction: T0 price $18.26; peak move +0.33%. Past moves do not guarantee future results.
Where can I get real-time $BRVE SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $BRVE via Telegram and the VIP Web Terminal from €10/month.